Privacy and data management in the era of massively parallel next-generation sequencing.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Exploring the advances of single-cell RNA sequencing in thyroid cancer: a narrative review.Medical oncology (Northwood, London, England) · 2023
   Review
2. The molecular landscape of neurological disorders: insights from single-cell RNA sequencing in neurology and neurosurgery.European journal of medical research · 2023
   Review
3. Clinical and ethical considerations of massively parallel sequencing in transplantation science.World journal of transplantation · 2013
   Article
4. Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.Journal of personalized medicine · 2013
   Article
5. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.Pharmacogenomics · 2012
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as